Investigational Drug Information for PF-07304814
What is the development status for investigational drug PF-07304814?
PF-07304814 is an investigational drug.
There have been 5 clinical trials for PF-07304814.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 4th 2020.
The most common disease conditions in clinical trials are COVID-19, Virus Diseases, and [disabled in preview]. The leading clinical trial sponsors are Pfizer, Medical Research Council, and National Heart, Lung, and Blood Institute (NHLBI).
There are eighteen US patents protecting this investigational drug and forty-one international patents.
Summary for PF-07304814
| US Patents | 18 |
| International Patents | 41 |
| US Patent Applications | 67 |
| WIPO Patent Applications | 56 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2020-08-04) |
| Vendors | 26 |
Recent Clinical Trials for PF-07304814
| Title | Sponsor | Phase |
|---|---|---|
| Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants | Pfizer | Phase 1 |
| PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | AIDS Clinical Trials Group | Phase 3 |
| PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | Cardiothoracic Surgical Trials Network (CTSN) | Phase 3 |
Clinical Trial Summary for PF-07304814
Top disease conditions for PF-07304814
Top clinical trial sponsors for PF-07304814
US Patents for PF-07304814
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-07304814 | ⤷ Start Trial | Niclosamide formulations for treating disease | Union Therapeutics AS | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Vidofludimus for use in the treatment or prevention of viral diseases | Immunic AG | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | Hokkaido University NUC , Shionogi and Co Ltd | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Methods for treating, ameliorating or preventing infections using drug and vaccination combination treatment | Topelia Aust Ltd Acn 652 771 670 , Topelia Aust Ltd 652 771 670 , Centre for Digestive Diseases Pty Ltd | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection | University of Arizona | ⤷ Start Trial |
| PF-07304814 | ⤷ Start Trial | Solid forms of emetine | Acer Therapeutics Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-07304814
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-07304814 | Australia | AU2022204775 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | Brazil | BR122023002208 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | Canada | CA3195272 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | Chile | CL2023003041 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | China | CN115038696 | 2041-04-14 | ⤷ Start Trial |
| PF-07304814 | China | CN115073431 | 2041-04-14 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
